Iovance Biotherapeutics (IOVA) Receivables (2023 - 2025)
Historic Receivables for Iovance Biotherapeutics (IOVA) over the last 3 years, with Q3 2025 value amounting to $66.8 million.
- Iovance Biotherapeutics' Receivables rose 1971.2% to $66.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.8 million, marking a year-over-year increase of 1971.2%. This contributed to the annual value of $69.3 million for FY2024, which is 4582052.98% up from last year.
- According to the latest figures from Q3 2025, Iovance Biotherapeutics' Receivables is $66.8 million, which was up 1971.2% from $59.9 million recorded in Q2 2025.
- Over the past 5 years, Iovance Biotherapeutics' Receivables peaked at $70.9 million during Q1 2025, and registered a low of $33000.0 during Q2 2023.
- In the last 3 years, Iovance Biotherapeutics' Receivables had a median value of $55.8 million in 2024 and averaged $39.4 million.
- Its Receivables has fluctuated over the past 5 years, first surged by 9566969.7% in 2024, then surged by 1971.2% in 2025.
- Iovance Biotherapeutics' Receivables (Quarter) stood at $151000.0 in 2023, then soared by 45820.53% to $69.3 million in 2024, then fell by 3.72% to $66.8 million in 2025.
- Its Receivables stands at $66.8 million for Q3 2025, versus $59.9 million for Q2 2025 and $70.9 million for Q1 2025.